InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $18.000 4.56 (33.93%)+
Announcement
Release
27 Feb 2026 9:53AM
Price at Release
$13.440
Full Release
download
Summary
Neuren Pharmaceuticals Limited's Appendix 4E and full-year accounts for 2025 report a net profit after tax of A$30.4 million, a significant decrease from A$142.0 million in 2024. The basic earnings per share declined to A$0.2373 from A$1.111 the previous year. Total revenue for 2025 was A$84.8 million, down from A$227.8 million in 2024, mainly due to the absence of one-time milestone payments received in the prior year. Despite this, royalty income increased by 15% to A$64.6 million. Corporate and administrative costs rose to A$6.2 million, reflecting higher share-based payment expenses. Cash and short-term investments rose to A$296.1 million. The company completed a share buy-back program costing A$39.6 million. The financial statements have been audited with an unqualified opinion.
Key Points
  • Net profit after tax for 2025 was A$30.4 million, compared to A$142.0 million in 2024.
  • Basic earnings per share for 2025 were A$0.2373.
  • Total revenue for 2025 was A$84.8 million, a 63% decrease from 2024.
  • Royalty income increased by 15% to A$64.6 million.
  • Corporate and administrative costs for 2025 were A$6.2 million.
  • Cash and short-term investments at the end of 2025 were A$296.1 million.
  • The company executed a A$39.6 million share buy-back.
  • Financial statements received an unqualified audit opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.